<DOC>
	<DOCNO>NCT00515138</DOCNO>
	<brief_summary>This study seek determine maximum tolerate dose bortezomib combination rituximab , ifosfamide , carboplatin , etoposide patient relapse primary refractory aggressive B-Cell Non-Hodgkin 's lymphoma ( diffuse large B-cell , mantle cell , follicular grade III , transform lymphoma ) . Subjects enrol cohort 3 bortezomib dose level , start 1 mg/m ( 2 ) , escalate 1.3 , 1.5 , 1.7 mg/m ( 2 ) . Bortezomib give day 1 ( prior rituximab ) 4 , rituximab 375 mg/m ( 2 ) /day day 2 , 3 , 4 21-day cycle . They also receive filgrastim day 6-13 pegfilgrastim day 6 .</brief_summary>
	<brief_title>A Pilot Study Standard-Dose Rituximab , Ifosfamide , Carboplatin Etoposide ( RICE ) Plus Bortezomib ( Velcade ) Dose-Escalating Fashion Patients With Relapsed Primary Refractory Aggressive B-Cell Non-Hodgkin 's Lymphoma Who Are Candidates Autologous Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Aggressive BCell Lymphoma , CD20 positive , first relapse refractory firstline chemotherapy Diffuse large Bcell Lymphoma , Mantle cell lymphoma , Follicular lymphoma ( Grade III ) , Transformed Follicular Lymphoma Rituximab allow Prior radiation allow 1870 year age ECOG performance status 02 HIV seronegative Measurable disease CT scan international work group response criteria No CNS involvement Subject consider candidate autologous stem cell transplant opinion treat physician Female subject either postmenopausal surgically sterilize willing use acceptable method birth control Male subject agree use acceptable method contraception duration study Platelet count &lt; 75 x 10 ( 9 ) /L Absolute neutrophil count &lt; 1.0 x 10 ( 9 ) /L Calculated measured creatinine clearance &lt; 60 mL/minute within 14 day enrollment Myocardial infarction within 6 month prior enrollment New York Hospital Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Subject hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Subject treat one prior chemotherapy regimen . Subject receive investigational drug 14 day enrollment . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>B-Cell NHL</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>RICE</keyword>
</DOC>